MS
DCOY

Maven Securities’s Decoy Therapeutics DCOY Stock Holding History

Maven Securities’s Portfolio DCOY Stock Details DCOY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-34
Closed -$1.24M – 1124
2021
Q3 		$1.24M Sell
34
-3
-8% -$104K 0.04% 375
2021
Q2 		$1.37M Sell
37
-17
-31% -$756K 0.06% 331
2021
Q1 		$2.78M Buy
+54
New +$3.1M 0.12% 158

Other funds holding DCOY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
XSC
X-Square Capital Guaynabo, Puerto Rico $394M AUM 44.75% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Maven Securities's DCOY Position: Q4 2021 in Review

Maven Securities sold out of Decoy Therapeutics (DCOY) in Q4 2021, closing a stake of 34 shares — an estimated $1.24M sold.

Maven Securities first reported a position in DCOY in Q1 2021 and held it in 3 quarters. The position peaked at $2.78M in Q1 2021. 17 funds tracked by Wall St. Rank hold DCOY as of Q4 2021.

  • Maven Securities reported no remaining Decoy Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Maven Securities sold 34 Decoy Therapeutics shares in Q4 2021, an estimated $1.24M.
  • Maven Securities first reported a position in Decoy Therapeutics in Q1 2021 and held it in 3 quarters.
  • Maven Securities's Decoy Therapeutics position peaked at $2.78M in Q1 2021.
  • 17 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q4 2021.

Based on Maven Securities's 13F filing for Q4 2021, filed 14 Feb 2022.